Agile Therapeutics Inc Down 11.80% To $0.57 After Earnings

Agile Therapeutics Inc (AGRX) said after close Thursday that it lost $2.71 per share in quarter two 2022.

On the revenue line, the company reported $2.1 million, beating estimates by $366 thousand.

In the same quarter a year ago, the company lost $8 per share on revenue of $1.2 million.

The stock is down 11.80% to $0.57 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 40. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.